PALO ALTO, Calif.--(BUSINESS WIRE)--March 9, 2006--StemCells, Inc. (NASDAQ: STEM) today announced that it has received approval from the Institutional Review Board (IRB) of the Oregon Health & Science University (OHSU) to initiate a Phase I clinical trial of the Company’s proprietary human neural stem cell product--HuCNS-SC (TM)--to treat infantile and late-infantile neuronal ceroid lipofuscinosis (NCL), two forms of a group of disorders often referred to as Batten disease. Batten disease is a rare and fatal neurodegenerative genetic condition affecting infants and children.
